AAPL332.77+0.50 (+0.15%) ▲|ABBV261.89+4.77 (+1.86%) ▲|ABT103.10+1.15 (+1.13%) ▲|ACN190.40+6.50 (+3.53%) ▲|ADBE262.85+10.62 (+4.21%) ▲|AMAT431.29-25.20 (-5.52%) ▼|AMD491.32-24.81 (-4.81%) ▼|AMGN379.28+1.93 (+0.51%) ▲|AMT177.33-0.52 (-0.29%) ▼|AMZN253.97-2.81 (-1.09%) ▼|AVGO347.41-14.58 (-4.03%) ▼|AXP325.23+0.54 (+0.16%) ▲|BA209.45-1.00 (-0.48%) ▼|BAC61.70-1.00 (-1.59%) ▼|BKNG175.91+1.99 (+1.14%) ▲|BLK1,066.20-13.46 (-1.25%) ▼|BMY64.19+0.55 (+0.86%) ▲|BNY159.54-3.12 (-1.92%) ▼|BRK-B513.71+3.34 (+0.65%) ▲|C134.54-4.28 (-3.08%) ▼|CAT786.89-31.68 (-3.87%) ▼|CL88.32+1.52 (+1.75%) ▲|CMCSA25.08-0.13 (-0.50%) ▼|COF205.93-2.37 (-1.14%) ▼|COP138.16+0.81 (+0.59%) ▲|COST916.02+11.25 (+1.24%) ▲|CRM256.53+8.81 (+3.56%) ▲|CSCO110.96-1.17 (-1.04%) ▼|CVS95.35+0.69 (+0.72%) ▲|CVX214.42+0.36 (+0.17%) ▲|DE687.34+11.60 (+1.72%) ▲|DHR199.93-0.21 (-0.10%) ▼|DIS108.66+2.11 (+1.98%) ▲|DUK118.78-0.64 (-0.54%) ▼|EMR147.94-4.26 (-2.80%) ▼|FDX312.60+1.83 (+0.59%) ▲|GD357.05+1.15 (+0.32%) ▲|GE317.11-6.55 (-2.02%) ▼|GEV876.00-81.27 (-8.49%) ▼|GILD145.53+1.81 (+1.26%) ▲|GM86.22+0.60 (+0.70%) ▲|GOOG342.05+6.60 (+1.97%) ▲|GOOGL345.39+6.89 (+2.03%) ▲|GS1,000.43-28.75 (-2.79%) ▼|HD309.87+1.13 (+0.36%) ▲|HON199.26-3.11 (-1.53%) ▼|IBM247.76+4.47 (+1.84%) ▲|INTC97.90-5.04 (-4.90%) ▼|INTU338.12+16.55 (+5.15%) ▲|ISRG374.04+4.89 (+1.32%) ▲|JNJ268.52+2.94 (+1.11%) ▲|JPM350.88-5.35 (-1.50%) ▼|KO88.91+0.62 (+0.70%) ▲|LIN462.96-3.27 (-0.70%) ▼|LLY1,146.89+31.19 (+2.80%) ▲|LMT529.15+4.96 (+0.95%) ▲|LOW197.92+1.10 (+0.56%) ▲|LRCX277.89-20.33 (-6.82%) ▼|MA575.11+5.92 (+1.04%) ▲|MCD257.99+5.46 (+2.16%) ▲|MDLZ62.29-0.15 (-0.24%) ▼|MDT93.12+2.16 (+2.37%) ▲|META659.63+11.60 (+1.79%) ▲|MMM160.99-3.98 (-2.41%) ▼|MO70.54+1.56 (+2.25%) ▲|MRK144.78+0.85 (+0.59%) ▲|MS209.52-4.87 (-2.27%) ▼|MSFT505.28+9.65 (+1.95%) ▲|MU924.41-50.85 (-5.21%) ▼|NEE81.85-0.47 (-0.56%) ▼|NFLX80.37+2.97 (+3.84%) ▲|NKE37.22+0.42 (+1.13%) ▲|NOW141.65+9.12 (+6.88%) ▲|NVDA211.93-6.36 (-2.91%) ▼|ORCL144.70-5.59 (-3.72%) ▼|PEP136.24-0.08 (-0.06%) ▼|PFE27.77+0.05 (+0.19%) ▲|PG146.06+0.79 (+0.54%) ▲|PLTR171.55+4.32 (+2.58%) ▲|PM193.36+2.30 (+1.20%) ▲|QCOM178.71-3.26 (-1.79%) ▼|RTX195.71-1.97 (-1.00%) ▼|SBUX99.41+0.67 (+0.68%) ▲|SCHW107.49+0.24 (+0.22%) ▲|SO87.59+0.42 (+0.48%) ▲|SPG206.18+1.35 (+0.66%) ▲|T26.35+0.29 (+1.09%) ▲|TMO607.77-2.05 (-0.34%) ▼|TMUS183.13+0.80 (+0.44%) ▲|TSLA363.34-2.10 (-0.57%) ▼|TXN262.23-6.47 (-2.41%) ▼|UBER71.61-0.06 (-0.08%) ▼|UNH381.93+5.16 (+1.37%) ▲|UNP284.78+0.38 (+0.13%) ▲|UPS101.25+0.97 (+0.96%) ▲|USB62.98+0.14 (+0.22%) ▲|V375.96+5.51 (+1.49%) ▲|VZ51.13+0.52 (+1.03%) ▲|WFC90.13-0.16 (-0.18%) ▼|WMT108.51+1.36 (+1.27%) ▲|XOM168.43+2.44 (+1.47%) ▲|AAPL332.77+0.50 (+0.15%) ▲|ABBV261.89+4.77 (+1.86%) ▲|ABT103.10+1.15 (+1.13%) ▲|ACN190.40+6.50 (+3.53%) ▲|ADBE262.85+10.62 (+4.21%) ▲|AMAT431.29-25.20 (-5.52%) ▼|AMD491.32-24.81 (-4.81%) ▼|AMGN379.28+1.93 (+0.51%) ▲|AMT177.33-0.52 (-0.29%) ▼|AMZN253.97-2.81 (-1.09%) ▼|AVGO347.41-14.58 (-4.03%) ▼|AXP325.23+0.54 (+0.16%) ▲|BA209.45-1.00 (-0.48%) ▼|BAC61.70-1.00 (-1.59%) ▼|BKNG175.91+1.99 (+1.14%) ▲|BLK1,066.20-13.46 (-1.25%) ▼|BMY64.19+0.55 (+0.86%) ▲|BNY159.54-3.12 (-1.92%) ▼|BRK-B513.71+3.34 (+0.65%) ▲|C134.54-4.28 (-3.08%) ▼|CAT786.89-31.68 (-3.87%) ▼|CL88.32+1.52 (+1.75%) ▲|CMCSA25.08-0.13 (-0.50%) ▼|COF205.93-2.37 (-1.14%) ▼|COP138.16+0.81 (+0.59%) ▲|COST916.02+11.25 (+1.24%) ▲|CRM256.53+8.81 (+3.56%) ▲|CSCO110.96-1.17 (-1.04%) ▼|CVS95.35+0.69 (+0.72%) ▲|CVX214.42+0.36 (+0.17%) ▲|DE687.34+11.60 (+1.72%) ▲|DHR199.93-0.21 (-0.10%) ▼|DIS108.66+2.11 (+1.98%) ▲|DUK118.78-0.64 (-0.54%) ▼|EMR147.94-4.26 (-2.80%) ▼|FDX312.60+1.83 (+0.59%) ▲|GD357.05+1.15 (+0.32%) ▲|GE317.11-6.55 (-2.02%) ▼|GEV876.00-81.27 (-8.49%) ▼|GILD145.53+1.81 (+1.26%) ▲|GM86.22+0.60 (+0.70%) ▲|GOOG342.05+6.60 (+1.97%) ▲|GOOGL345.39+6.89 (+2.03%) ▲|GS1,000.43-28.75 (-2.79%) ▼|HD309.87+1.13 (+0.36%) ▲|HON199.26-3.11 (-1.53%) ▼|IBM247.76+4.47 (+1.84%) ▲|INTC97.90-5.04 (-4.90%) ▼|INTU338.12+16.55 (+5.15%) ▲|ISRG374.04+4.89 (+1.32%) ▲|JNJ268.52+2.94 (+1.11%) ▲|JPM350.88-5.35 (-1.50%) ▼|KO88.91+0.62 (+0.70%) ▲|LIN462.96-3.27 (-0.70%) ▼|LLY1,146.89+31.19 (+2.80%) ▲|LMT529.15+4.96 (+0.95%) ▲|LOW197.92+1.10 (+0.56%) ▲|LRCX277.89-20.33 (-6.82%) ▼|MA575.11+5.92 (+1.04%) ▲|MCD257.99+5.46 (+2.16%) ▲|MDLZ62.29-0.15 (-0.24%) ▼|MDT93.12+2.16 (+2.37%) ▲|META659.63+11.60 (+1.79%) ▲|MMM160.99-3.98 (-2.41%) ▼|MO70.54+1.56 (+2.25%) ▲|MRK144.78+0.85 (+0.59%) ▲|MS209.52-4.87 (-2.27%) ▼|MSFT505.28+9.65 (+1.95%) ▲|MU924.41-50.85 (-5.21%) ▼|NEE81.85-0.47 (-0.56%) ▼|NFLX80.37+2.97 (+3.84%) ▲|NKE37.22+0.42 (+1.13%) ▲|NOW141.65+9.12 (+6.88%) ▲|NVDA211.93-6.36 (-2.91%) ▼|ORCL144.70-5.59 (-3.72%) ▼|PEP136.24-0.08 (-0.06%) ▼|PFE27.77+0.05 (+0.19%) ▲|PG146.06+0.79 (+0.54%) ▲|PLTR171.55+4.32 (+2.58%) ▲|PM193.36+2.30 (+1.20%) ▲|QCOM178.71-3.26 (-1.79%) ▼|RTX195.71-1.97 (-1.00%) ▼|SBUX99.41+0.67 (+0.68%) ▲|SCHW107.49+0.24 (+0.22%) ▲|SO87.59+0.42 (+0.48%) ▲|SPG206.18+1.35 (+0.66%) ▲|T26.35+0.29 (+1.09%) ▲|TMO607.77-2.05 (-0.34%) ▼|TMUS183.13+0.80 (+0.44%) ▲|TSLA363.34-2.10 (-0.57%) ▼|TXN262.23-6.47 (-2.41%) ▼|UBER71.61-0.06 (-0.08%) ▼|UNH381.93+5.16 (+1.37%) ▲|UNP284.78+0.38 (+0.13%) ▲|UPS101.25+0.97 (+0.96%) ▲|USB62.98+0.14 (+0.22%) ▲|V375.96+5.51 (+1.49%) ▲|VZ51.13+0.52 (+1.03%) ▲|WFC90.13-0.16 (-0.18%) ▼|WMT108.51+1.36 (+1.27%) ▲|XOM168.43+2.44 (+1.47%) ▲|
22.2 C
New York
Monday, September 14, 2026

Tag: development

newssourceFORcompanyinformationcontent1releasesmarket

Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., July 25, 2025 /PRNewswire/ -- Shanton Pharma,...

Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., July 25, 2025 /PRNewswire/ -- Shanton Pharma,...

Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., July 25, 2025 /PRNewswire/ -- Shanton Pharma,...

FILM & TAPE EXPO 2025: Asia’s Leading Functional Film and Adhesive Tape Show Returns to Shenzhen, Featuring Sustainability and Innovation.

SHENZHEN, China, July 25, 2025 /PRNewswire/ -- FILM & TAPE EXPO 2025, Asia's premier B2B expo for functional film and industrial adhesive tapes, will...

STL reports Q1 FY26 results; continued positive momentum in Revenue and Order Book

YoY growth in Revenue and EBITDA of ~17% and ~94%, respectivelyOrder intake of INR 1,500+ Cr in Q1 FY26MUMBAI, India, July 25, 2025 /PRNewswire/...

Data Center Infrastructure Market Experiences Growth of 10.20 billion by 2031 at CAGR of 16.1% | The Insight Partners

NEW YORK, July 25, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global data center infrastructure market is...

Data Center Infrastructure Market Experiences Growth of 10.20 billion by 2031 at CAGR of 16.1% | The Insight Partners

NEW YORK, July 25, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global data center infrastructure market is...

Nelipak® Breaks Ground on New Healthcare Packaging Facility in Grecia, Alajuela Costa Rica

Nelipak® Corporation (“Nelipak®”) has officially broken ground on its new, state-of-the-art production facility in Costa Rica Green Valley in Alajuela.

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year clinical efficacy data from its phase 2 trial with lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2025 to be held in Berlin, Germany, from October 17-21, 2025.

Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

VYJUVEK approved for the treatment of DEB from birth with flexible administration options including home dosing and the option for administration by the patient or their family

LOBO EV Technologies Ltd. Issues Statement Regarding Recent Market Activity

WUXI, China, July 25, 2025 (GLOBE NEWSWIRE) -- LOBO EV Technologies Ltd. (Nasdaq: LOBO) (“LOBO” or the “Company”), a developer and manufacturer in electric mobility and intelligent systems, today issued a statement regarding recent trading activity in its common stock.

Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies

Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committed 
Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committed

Stuhini Appoints New Corporate Secretary

VANCOUVER, BC, July 25, 2025 /CNW/ - Stuhini Exploration Ltd. (the "Company" or "Stuhini") (TSXV: STU) (OTCQB: STXPF) is pleased to announce the appointment of...

Neinor Homes accelerates growth in 1H25 with 1,701# pre-sold (+45%), while reaffirms its FY25 targets

MADRID, 25 July 2025 – Neinor Homes (“Neinor”) (HOME SM), the leading residential platform in Spain, has announced its results for the first half of 2025, confirming the continued growth of its Asset Management business, solid operating margins, and a record commercialization activity. The period also marks an acceleration in the Company’s investment strategy with the launch of a voluntary tender offer for 100% of Aedas Homes’ capital.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDevelopment

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers